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Natural Products
Iso-maleimycin, a Constitutional Isomer of Maleimycin, from
Streptomyces sp. QL37
Michiel T. Uiterweerd,[a] Isabel Nuñez Santiago,[b] Helga van der Heul,[b]
Gilles P. van Wezel,[b] and Adriaan J. Minnaard*[a]
Abstract: Iso-maleimycin, a previously unknown constitutional
isomer of the antibiotic maleimycin, has been detected in an
extract of Streptomyces sp. QL37. Chemical synthesis of both
maleimycin (20 % yield over seven steps) and iso-maleimycin,
(15 % yield over six steps) allowed access to reference materials
for identification. Gas Chromatography coupled Mass Spec-
Introduction
Bacteria of the actinobacterial genus Streptomyces are known to
produce a wide range of bioactive natural products, including
antibiotics, anticancer compounds, and immunosuppressants.[1]
These natural products include a range of maleimide-contain-
ing metabolites, of which showdomycin[2] (1) and maleimycin[3]
(2) (Figure 1) are antibiotics produced by Streptomyces show-
doensis. Maleimycin 2 was discovered independently after the
discovery of 1, as it was detected by further analyzing UV ab-
sorption bands of culture extracts.[3] After isolation, the struc-
ture of 2 was elucidated mainly by 1H-NMR, 13C-NMR and mass
spectrometry.[3] Although 1 and 2 originate from the same or-
ganism, feeding experiments with 3H, 13C and 14C-labeled acet-
ate and glutamate revealed that the formation of the maleimide
ring in these compounds occurs via two different pathways.[3,4a]
More recently, the showdomycin biosynthetic gene cluster
(BGC) of S. showdoensis ATCC 15227 has been unraveled, by
which a more detailed biosynthetic pathway of showdomycin
has been proposed.[4b] A detailed biosynthetic pathway of 2
however remains unknown. Naturally occurring derivatives of
maleimycin 2 have been isolated from S. nitrosporeus.[5] The
diastereomeric nitrosporeusine A (3a) and nitrosporeusine B
(3b) consist of a maleimycin moiety linked to a p-hydroxy-
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trometry (GC-MS) analysis demonstrated that of the two iso-
mers, only iso-maleimycin was present in the extract. This find-
ing supports our hypothesis that iso-maleimycin is a biosyn-
thetic intermediate of lugdunomycin. Iso-maleimycin displays
low antibiotic activity, with a Minimum Inhibitory Concentration
(MIC) value on both E. coli and B. subtilis of 250 μg/mL.
benzoate thioester. Both compounds have also been chemically
synthesized, which was accomplished by a thio-Michael addi-
tion of p-hydroxybenzothioic S-acid to synthetic (S)-2.[6c,6d]
Figure 1. Metabolites from the Streptomyces genus containing maleimide
(blue) and succinimide moieties (red).
Recently, we reported the isolation and characterization of
several previously undescribed angucycline derivatives in the
extracts of Streptomyces sp. QL37,[7a] an antibiotic-producing ac-
tinomycete originating from mountain soil.[7b] Noticeable was
the succinimide-containing compound lugdunomycin 4, an
antibiotic with a rare chemical structure derived from the angu-
cycline polyketide backbone. Angucyclines and their derivatives
are the most diverse known family of polyketides, many of
which have antibacterial and/or anticancer activity.[8a,b] There-
fore, these compounds are of great interest for the pharmaceu-
tical industry and for medical applications. During our investiga-
tions, a trace compound with the nominal mass of 2 was de-
tected by LC-MS. As inspection of 4 suggested constitutional
isomer 5, rather than 2, to be involved in its biosynthesis,[7a] we
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nary supporting evidence for the presence of 2 or 5 was ob-
tained by additional MS/MS fragmentation experiments and we
dubbed the name of 5 to be iso-maleimycin.[7a]
Structurally, the maleimycins 2 and 5 are composed of an
uncommon bicyclic 5,6-dihydrocyclopenta[c]pyrrole-1,3(2H,4H)-
dione backbone. Maleimycin 2 carries a hydroxy function at the
allylic C4 position and is chiral. A total synthesis of racemic 2
by Singh and Weinreb[6a] was reported in 1976, however assign-
ment of the absolute configuration was performed later in syn-
thetic studies by Philkana et al.[6c] in 2015. The configuration
turned out to be R. In iso-maleimycin 5 the hydroxy group is
positioned at C5, so as a result 5 is achiral.
As the compound of interest was detected only in small
amounts, no attempt was made to isolate it. Instead we em-
barked on the chemical synthesis of both 2 and 5 to be able




In the report by Weinreb and Singh,[6a] 2 was synthesized from
6 by allylic bromination, followed by nucleophilic substitution
with silver trifluoroacetate and subsequent hydrolysis of the re-
sulting trifluoroacetate ester (Scheme 1). Alternatively, 2 can be
made by direct allylic oxidation with SeO2 of 6.[6c,6d] Compound
Scheme 1. Retrosynthetic analysis of maleimycin 2.
Scheme 2. Synthesis of maleimycin 2.
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6 in turn has been prepared starting from cyclopent-1-ene-1,2-
dicarboxylic acid (7a).[9] Amidation of 7a, followed by cyclisa-
tion would then yield 6. In turn, 7a can be obtained by cycliza-
tion of dimethyl α,α′-dibromopimelate 10 with sodium hydride
in DMF, followed by acidic hydrolysis of the resulting diester
(dimethyl cyclopent-1-ene-1,2-dicarboxylate).[9] Compound 10
can be readily obtained by Hell-Vollhardt–Zelinski bromination
of pimelic acid.[9] Unfortunately, when we attempted the so-
dium hydride mediated cyclisation procedure of 10 on a multi-
gram scale, the main product isolated was the isomeric di-
methyl cyclopent-2-ene-1,2-dicarboxylate.
Therefore, we sought for alternative strategies to arrive at
7a/b. In the literature[10a,10b] it has been described that ethyl
ester 7b can be obtained in high yield, in two steps, starting
from 8. These steps include the conversion of 8 into its corre-
sponding enol triflate, which is then transformed into 7b by
means of a palladium catalyzed carboxylation reaction.[10a,10b]
Indeed, commencing the synthesis of compound 2
(Scheme 2), enol triflate 11 was readily prepared from Dieck-
mann product 8 in 94 % yield, by treatment with sodium
hydride and trapping the resulting enolate with Tf2O.[10a,10b]
Enol triflate 11 was subjected to a palladium catalyzed carbox-
ylation, as reported by Yoshimitsu et al.[10a] Treatment of 11
with sodium formate, acetic anhydride and catalytic (5 mol-%)
Pd(OAc)2 in the presence of LiCl provided carboxylic acid 7a in
near quantitative yield. As anticipated, 7a could be converted
into amide-ester 12 by exposure of the corresponding acid
chloride to concentrated aqueous ammonia under Schotten–
Baumann conditions.[11] This procedure gave amide 12 in 86 %
yield.
Subsequently, cyclization conditions were investigated in or-
der to arrive at the desired imide 6. Due to the presence of
considerable ring strain in 6, cyclisation of the imide-precursor
requires forcing conditions. Weinreb and Singh[6a] obtained 6
by a two step approach; first converting the acid-amide, derived
from compound 7b, into the corresponding nitrile, and then
cyclisation to 6 in refluxing trifluoroacetic anhydride. We aimed
for the direct conversion of 12 into 6 instead. It was hypothe-
sized that cyclization would occur after deprotonation of amide
12 with a strong base. Fortunately, when a solution of 12 in
THF was added to NaH, it underwent immediate conversion
into imide 6. It was observed by analytical TLC, however, that
some polar side-products were formed, presumably caused by
degradation or polymerisation of the starting material. Com-
pound 6 was isolated in an appreciable 60 % yield. This result
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ously.[6a–6d] With 6 in hand we completed the synthesis accord-
ing to the procedure of Weinreb and Singh[6a] to obtain racemic
maleimycin. Maleimycin 2 was prepared in 20 % overall yield in
seven steps.
Synthesis of Iso-maleimycin 5
It was envisioned (Scheme 3) that the maleimide unit in 5 could
be constructed using the same cyclisation strategy as in the
synthesis of 2. This required the synthesis of 14a or 14b, in
turn planned to be prepared from commercially available 15,
by reduction of the ketone followed by introduction of the dou-
ble bond.
The synthesis of iso-maleimycin (5) (Scheme 4) commenced
with the reduction of commercially available rac-15 with NaBH4
in methanol. The resulting crude 16 was directly treated with
TBDPSCl and imidazole in DMF,[12] to provide 17 in 77 % yield
based on 15. A key step was the preparation of compound 14b
by the introduction of the double bond. According to litera-
ture,[13] 17 was treated with an excess of LDA to form the
mono-enolate, which was treated with a stoichiometric amount
of iodine in THF at –78 °C to generate the corresponding
iodinated intermediate. This intermediate then likely reacted
with a second equivalent of LDA providing the corresponding
elimination product 14b, which was isolated in 74 % yield.
The next phase was to access 18. Based on previous experi-
ments, it was expected that mono-amide 18 could be prepared
from mono-acid 14a, which in turn was envisioned to be ob-
tained from hydrolysis of compound 14b. It was found that 14b
Scheme 3. Retrosynthetic analysis of iso-maleimycin 5.
Scheme 4. Total synthesis of iso-maleimcyin 5.
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could be hydrolyzed with potassium hydroxide in a water/THF/
MeOH mixture, yielding mono-acid 14a in 64 % yield. Subse-
quently 14a was converted into mono-amide 18, using the
same Schotten–Baumann procedure used in the synthesis of
9.[11] With this approach, the mono-amide was obtained in 54 %
yield, as tarry products were formed in significant amounts. To
reduce loss of material throughout the synthesis, an alternative
single-step procedure was sought for the conversion of diester
14b into mono-amide 18. Weinreb and co-workers[14] had
reported that aluminium amide complexes of the type
[AlCl(CH3)NR2] (R = H or alkyl) can be used to convert esters
into their corresponding amide. The reagent [AlCl(CH3)NH2] was
generated from ammonium chloride and Al(CH3)3 (as a solution
in toluene), to which 14b was added subsequently. We were
delighted to observe that in this way 18 was prepared in 53 %
yield directly from 14b.
With a sufficient amount of 18 in hand, cyclisation to the
corresponding imide 19 was studied. As expected, when 18
was treated with NaH in THF at 0 °C, 19 was obtained in 65 %
yield. We occasionally observed that upon addition of the sub-
strate to the sodium hydride suspension, the reaction did not
initiate spontaneously. We speculate this is caused by the poor
solubility of sodium hydride in THF. The issue could be readily
solved by pre-mixing 18 with 1.3 equiv. of 15-crown-5 before
adding it as a solution in THF to the sodium hydride, affording
the desired product without affecting the yield. It has been
proposed that 15-crown-5 acts as a phase transfer reagent aid-
ing solubilization of sodium hydride, thereby increasing its ba-
sicity.[15] Due to immediate initiation in presence of 15-crown-
5, we anticipate that at larger scale potential runaway reactions
can also be prevented. Finally, desilylation of 19 was performed
using TBAF in THF,[12] which gave iso-maleimycin 5 in 76 %
yield. Overall, over the shortest sequence in six steps, com-
pound 5 was obtained in 15 % yield.
Identification of Iso-maleimycin 5 in Extracts of S. sp
QL37, Using GC-MS
Streptomyces sp. QL37 was isolated from soil in the Qinling
mountains (P. R. China) and deposited to the collection of the
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Netherlands, under deposit number 138593.[7a,7b] The extract
was prepared as indicated in the experimental section. GC-MS
was selected for the analysis due to the low molecular mass and
hence relatively volatile nature of 2 and 5. In addition, structural
information can be obtained from the EI fragmentation spectra
corresponding to the TIC chromatograms. The analysis was per-
formed by injecting samples of compound 2 and compound 5
(0.23 mg/mL), and also a sample of the extract (1 mg/mL). It
was found by comparing the chromatograms and their corre-
sponding EI mass spectra that S. sp. QL37 produces iso-malei-
Figure 2. Stacked GC-MS TIC chromatograms of synthetic 2 and 5, and an extract of S. sp. QL37. Apparatus and settings: a Shimadzu GC-2010 gas chromato-
graph equipped with an HP-1 column, 100 % dimethylsiloxane, (30 m L × 0.25 mm Ø × 0.25 μm thickness), temperature program, 150 °C hold for 5 min, then
increase 150 °C to 200 °C with 20 °C/min, finally 3 min hold at 200 °C. For the synthetic samples, split ratio: 20.0, for the extract, split ratio: 10.0, carrier gas:
He, flow 21.9 mL/min, pressure 82.7 kPa.
Figure 3. Mass spectra of synthetic 2, and 5 and a matching signal found in S. sp. QL37 for iso-maleimycin. aConditions and settings: Shimadzu GC-MS-QP2010
gas chromatograph mass spectrometer, Electron Impact (EI) ionisation, ionization energy 70 eV. A. mass spectrum of the suspected peak in the extract of S.
sp. QL37 showing the presence of compound 5; B. mass spectrum of synthetic 5; C. mass spectrum of synthetic 2[16].
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mycin 5 but not maleimycin 2. In the TIC chromatogram (Fig-
ure 2) of the isolate, based on retention times two signals were
identified which potentially corresponded to 2 or 5. Closer in-
spection and comparison with synthetic 5 indicated that this
compound is present in the extract, which was confirmed by
matching fragmentation spectra (Figure 3).
Antibiotic Assays
Since compound 2 is a known antibiotic,[3,6] it was anticipated
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closely related structure. 5 Was tested for antibiotic activity, and
it was found that 5 displayed growth inhibition in a disk diffu-
sion assay (1000 μg/mL) on Escherichia coli and Bacillus subtilis.
Following these results, the Minimum Inhibitory Concentrations
(MIC)[17,18] for 5 were determined. The MIC of 5 was found to
be 250 μg/mL for E. coli ASD219 and 250 μg/mL for B. subtilis.
MIC values for (rac)-2 were also determined for comparison, and
were found to be 31 μg/mL on E. coli and 125 μg/mL for B.
subtilis; indicating that 2 is a more potent antibiotic than 5.
Conclusion
In conclusion, iso-maleimycin 5, a maleimide-containing metab-
olite, and a constitutional isomer of maleimycin 2, has been
identified in Streptomyces sp. QL37. 5 has been synthesized, af-
fording the product in 15 % overall yield over six steps. Addition-
ally, maleimycin 2 was also synthesized according to a modified
synthetic sequence and the compound was obtained in 20 %
overall yield over seven steps. Comparison of the synthetic com-
pounds by GC-MS with an extract of S. sp. QL37 confirmed un-
ambiguously that iso-maleimycin is produced by S. sp. QL37.
However, the previously described maleimycin 2 was not de-
tected in the extract. Detection of 5 serves as evidence for our
hypothesis that it is a biosynthetic precursor of 4. Currently we
are interested in the exact biosynthetic origin of 5, its relation-
ship with maleimycin, and its role in the biosynthesis of lugduno-
mycin 4. Antibiotic assays of 5 showed that it displays weak
antibiotic activity towards gram positive B. subtilis and gram neg-
ative E. coli as the MIC values were found to be 250 μg/mL. In
these assays iso-maleimycin 5 is less potent than maleimycin 2.
Experimental Section
Synthetic Chemistry Experiments
General: All moisture and oxygen sensitive reactions were executed
under a N2 atmosphere. All reaction solvents were purchased from
commercial vendors and used without further purification unless
specified otherwise. Reagents were purchased from chemical ven-
dors and used without further treatment or purification, unless
stated otherwise. NMR spectra were recorded on an Agilent 400
NMR spectrometer, detected 1H-nuclei at 400 MHz, 13C-nuclei at
101 MHz and 19F-nuclei at 376 MHz. Reported chemical shifts are
given in ppm, relative to the residual solvent signal. IR spectroscopic
analyses were done using a Perkin-Elmer Spectrum Two UATR FT-
IR spectrometer. Analytical TLC plates, provided with a fluorescent
marker, were obtained from Merck Chemicals. TLC spots were visu-
alised by means of a UV lamp or appropriate staining reagent.
HRMS was executed on a Thermo-Fisher Orbitrap Electron Spray
Ionization (ESI) mass spectrometer at positive ionization mode, un-
less specified otherwise.
Ethyl 2-{[(Trifluoromethyl)sulfonyl]oxy}cyclopent-1-ene-1-carb-
oxylate (11): Prepared according to the procedure by Ralph et
al.[10b] by starting from ethyl 2-oxocyclopentane-1-carboxylate 8
(10.0 g, 64.0 mmol ). The product was purified by flash column
chromatography (Et2O/pentane, 5:95), affording 11 (17.3 g,
60.0 mmol, 94 % yield) as a colourless oil. 1H-NMR (400 MHz, CDCl3)
δ = 4.25 (q, J = 7.1 Hz, 2H), 2.84–2.56 (m, 4H), 2.12–2.89 (m, 2H),
1.30 (t, J = 7.1 Hz, 3H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 162.3,
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153.4, 123.4, 118.3 (q, JCF = 320.0 Hz), 61.1, 32.7, 29.2, 18.8,
14.0 ppm. 19F-NMR (376 MHz, CDCl3) δ = –74.6 ppm. 1H-NMR and
13C-NMR data were in agreement with those reported in the litera-
ture.[10b]
2-(Ethoxycarbonyl)cyclopent-1-ene-1-carboxylic Acid (7a): Pre-
pared according to the procedure by Ralph et al.[10b] by starting
from enol triflate 11 (3.00 g, 10.4 mmol), providing 7a as a brown
oil (1.78 g, 9.65 mmol, 93 % yield) in sufficient purity to be used in
the next step. 1H-NMR (400 MHz, CDCl3) δ = 4.33 (q, J = 7.1 Hz, 2H),
2.94–2.81 (m, 4H), 1.87 (tt, J = 8.2, 7.4 Hz, 2H), 1.34 (t, J = 7.1 Hz,
3H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 168.3, 163.6, 148.4, 138.7,
63.1, 36.9, 35.7, 20.2, 13.9 ppm. Physical data were in accordance
with those reported in the literature.[10b]
Ethyl 2-Carbamoylcyclopent-1-ene-1-carboxylate (12): Accord-
ing to a modified literature procedure,[11] crude mono-ester 7a
(2.00 g, 10.7 mmol) was dissolved in CH2Cl2 (40 mL), and 2 drops
of DMF were added. The solution was cooled on ice, SOCl2 (3.2 mL,
5.17 g, 43.4 mmol) was added dropwise via syringe, and the reac-
tion was stirred for 40 min while cooling was maintained. Then the
solution was allowed to reach r.t. while it was stirred for 30 min.
The remaining solution was carefully added dropwise to ice cold
concentrated 14 M NH4OHaq (100 mL), the resulting biphasic mix-
ture was extracted with EtOAc (3 × 75 mL). The combined organic
layers were washed with 1 M HClaq (1 × 50 mL). The organic layers
were dried with MgSO4 and concentrated by means of rotary evap-
oration to provide the product as a grey crystalline solid, (1.70 g,
9.25 mmol, 86 % yield) which was of sufficient purity to be used in
the next step. Mp 72–74 °C; 1H-NMR (400 MHz, CDCl3) δ = 8.44 (bs,
1H, NH), 5.88 (bs, 1H, NH), 4.23 (q, J = 7.1 Hz, 2H), 2.89–278 (m, 4H),
1.84 (quint., J = 7.7 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H) ppm. 13C-NMR
(101 MHz, CDCl3) δ = 166.44, 166.41, 147.8, 135.4, 61.4, 36.8, 36.2,
20.7, 14.0 ppm. HRMS calcd. for C9H13NO3 [M + H]+: 184.0968, found
184.0969.
5,6-Dihydrocyclopenta[c]pyrrole-1,3(2H,4H)-dione (6): A round-
bottomed flask was equipped with a stir bar and NaH 60 % suspen-
sion in mineral oil (482 mg, 12.1 mmol) which was rinsed with pent-
ane three times. A solution of 12 (1.70 g, 9.28 mmol) in 44 mL of
THF was added dropwise via syringe, while cooling the reaction
mixture on ice. After 15 min, when H2 evolution had ceased, the
reaction mixture was quenched by adding acetic acid (0.7 mL). The
mixture was diluted with water and extracted with EtOAc (3 ×
50 mL), the combined organic layers were dried with MgSO4 and
concentrated in vacuo. The product was purified by means of col-
umn chromatography (EtOAc/pentane, 25:85), to give the pure im-
ide as a white crystalline solid (765 mg, 5.58 mmol, 60 % yield).
Alternatively, an analytically pure sample was obtained by means
of recrystallization from CHCl3/pentane (50:50) and cooling to
–78 °C, in comparable yield and purity. Mp 184–186 °C*; 1H-NMR
(400 MHz, CDCl3) δ = 7.31 (br s, 1H, NH), 2.65 (t, J = 7.2 Hz, 4H),
2.52–238 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3) δ = 167.0, 154.6,
27.5, 26.4 ppm. *The previously reported melting point for this com-
pound is 177–179 °C. 1H-NMR data are in agreement with those
reported in the literature.[6a]
(R/S)-4-Hydroxy-5,6-dihydrocyclopenta[c]pyrrole-1,3(2H,4H)-di-
one, (rac)-maleimycin (2): Imide 6 (763 mg, 5.56 mmol), NBS
(1.09 g, 6.12 mmol) and AIBN (137 mg, 0.84 mmol, 15 mol-%) were
suspended in benzene (22 mL), and the mixture was heated to
80 °C followed by stirring for 1 h. The reaction mixture was diluted
with water (100 mL), extracted with EtOAc (5 × 50 mL), the com-
bined organic layers were dried with MgSO4 and concentrated to
provide the crude allylic bromide as a brown oil which rapidly crys-
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and purified by flash column chromatography (EtOAc/pentane,
10:90 and 30:70) which provided a white crystalline solid (921 mg,
4.26 mmol, 77 % yield) which was immediately used in the next
step. 1H-NMR (400 MHz, CDCl3) δ = 7.05 (bs, 1H, NH), 5.14 (dt, J =
7.2, 1.8 Hz, 1H), 3.08 (td, J = 14.9, 6.9 Hz, 1H), 2.93 (dtd, J = 18.6,
7.0, 2.5 Hz, 1H), 2.80 (ddt, J = 14.7, 7.2, 1.3 Hz, 1H), 2.70 (ddd, J =
18.6, 8.3, 1.7 Hz, 1H) ppm. Following the procedure by Weinreb and
Singh;[6a] the reaction of allylic bromide (920 mg, 4.26 mmol) and
silver trifluoroacetate (1.13 g, 5.11 mmol) provided the crude ester
(922 mg), which was obtained as a pale orange oil. 1H-NMR
(400 MHz, CDCl3) δ = 7.33 (bs, 1H, NH), 6.19 (dt, J = 7.7, 2.5 Hz,
1H), 2.82–272 (m, 2H), 2.55–245 (m, 1H) ppm. Subsequently, the
trifluoroacetate ester (922 mg) was hydrolysed, and purified by
means of column chromatography (EtOAc/pentane, 30:70 and
50:50), which afforded rac-maleimycin 2 (409 mg, 2.67 mmol, 63 %
yield, based on the bromide), as a white crystalline solid. Mp 109–
112 °C; 1H-NMR (400 MHz, MeOD) δ = 5.09–5.01 (m, 1H), 2.84–2.64
(m, 2H), 2.57–2.45 (m, 1H), 2.26–2.13 (m, 1H) ppm. 13C-NMR
(101 MHz, MeOD) δ = 168.1, 167.5, 156.4, 153.1, 69.7, 38.2,
23.6 ppm. HRMS (negative mode) calcd. for C7H7NO3 [M – H]–:
152.0353, found 152.0356. Physical data of maleimycin were in
agreement with those reported in the literature.[6a–6d]
Dimethyl (1S,2S)-4-[(tert-Butyldiphenylsilyl)oxy]cyclopentane-
1,2-dicarboxylate (17): To a solution of racemic (trans)-dimethyl 4-
oxocyclopentane-1,2-dicarboxylate 15 (2.00 g, 9.99 mmol) in MeOH
(40 mL) was added NaBH4 (189 mg, 5.00 mmol), while cooling on
ice. The solution was left stirring at 0 °C for 20 min and quenched
with 1 M HClaq (30 mL) followed by dilution with water (40 mL). The
solution was extracted with EtOAc (3 × 40 mL) and the combined
organic layers were dried with MgSO4, concentration by rotary
evaporation provided the crude alcohol 16 as a colourless oil
(1.70 g) in sufficient purity to be used in the next step. 1H-NMR
(400 MHz, CDCl3) δ = 4.41 (tt, J = 4.6, 2.3 Hz, 1H), 3.72 (s, 3H), 3.71
(s, 3H), 3.43 (dt, J = 10.0, 7.7 Hz, 1H), 3.25 (ddd, J = 10.0, 7.0, 4.8 Hz,
1H), 2.25 (ddd, J = 14.6, 10.0, 5.0 Hz, 1H), 2.15 (ddt, J = 13.3, 8.3,
2.2Hz, 1H), 2.05–1.92 (m, 2H) ppm. 13C-NMR (101 MHz, CDCl3) δ =
176.1, 175.2, 72.9, 52.4, 52.2, 45.3, 45.2, 39.9, 38.6 ppm. HRMS calcd.
for C9H14O5 [M + Na]+: 225.0734, found 225.0734. Crude 16 (1.70 g,
8.41 mmol) and imidazole (1.15 g, 16.8 mmol) were dissolved in
DMF (34 mL), the solution was cooled in an ice bath. TBDPSCl
(2.4 mL, 2.50 g, 9.01 mmol) was added dropwise via syringe, after
which it was allowed to reach r.t. and left stirring overnight. The
reaction mixture was diluted with water (50 mL) and extracted with
EtOAc (3 × 50 mL). The combined organic layers were washed with
brine (4 × 50 mL), dried with MgSO4 and concentrated by means of
rotary evaporation. The crude material was purified by flash column
chromatography (Et2O/pentane, gradient 10:90 and 20:80), to afford
17 (3.38 g, 7.67 mmol, 77 % yield, over two steps) as a colourless
oil. 1H-NMR (400 MHz, CDCl3) δ = 7.66–7.59 (m, 4H), 7.47–7.33 (m,
6H), 4.31 (pent., J = 4.3 Hz, 1H), 3.71 (s, 3H), 3.67 (s, 3H), 3.61 (dt,
J = 9.8, 8.0 Hz, 1H), 3.18–305 (m, 1H), 2.17–1.96 (m, 3H), 1.75 (ddd,
J = 13.2, 8.9, 5.1 Hz, 1H), 1.03 (s, 9H) ppm. 13C-NMR (101 MHz, CDCl3)
δ = 175.6, 174.7, 135.73, 135.69, 133.9, 133.8, 129.7, 127.7, 127.6,
74.0, 52.1, 52.0, 45.0, 44.3, 39.7, 39.1, 26.7, 19.4 ppm. HRMS calcd.
for C25H32O5Si [M + Na]+: 463.1911, found 463.1911.
Dimethyl 4-[(tert-Butyldiphenylsilyl)oxy]cyclopent-1-ene-1,2-
dicarboxylate (14b): According to a modified literature proce-
dure,[13] LDA was generated by adding nBuLi (1.6 M solution in hex-
anes, 7.6 mL, 12.1 mmol) to a solution of N,N-diisopropylamine*
(1.8 mL, 12.8 mmol) in dry THF (10 mL), at –78 °C. Compound 17
(2.35 g, 5.34 mmol) was dissolved in dry THF (25 mL) and added to
the reaction mixture dropwise. To the resulting bright yellow solu-
tion was added a solution of iodine (1.42 g, 5.61 mmol) in THF
Eur. J. Org. Chem. 2020, 5145–5152 www.eurjoc.org © 2020 The Authors published by Wiley-VCH GmbH5150
(31 mL). Subsequently, the purple-brown solution was allowed to
reach r.t. and carefully quenched by adding 1 M HClaq (50 mL). The
mixture was extracted with EtOAc (3 × 50 mL), the combined or-
ganic layers were washed with brine (50 mL), dried with MgSO4
and concentrated by means of rotary evaporation. The concentrate
was purified by column chromatography (EtOAc/pentane, gradient
10:90 and 20:80), to afford 14b as a viscous pale yellow syrup
(1.73 g, 3.94 mmol, 74 % yield). 1H-NMR (400 MHz, CDCl3) δ = 7.67–
7.61 (m, 4H), 7.46–7.34 (m, 6H), 4.55 (tt, J = 6.4, 4.4 Hz, 1H), 3.76 (s,
6H), 2.87–2.69 (m, 4H), 1.05 (s, 9H) ppm. 13C-NMR (101 MHz, CDCl3)
δ = 165.6, 137.4, 135.7, 133.7, 129.8, 127.7, 71.5, 52.1, 44.1, 26.8,
19.0 ppm. HRMS calcd. for C25H30O5Si [M + Na]+: 439.1935, found
439.1933. *N,N-diisopropylamine was distilled from KOH pellets be-
fore use.
4-[(tert-Butyldiphenylsilyl)oxy]-2-(methoxycarbonyl)cyclopent-
ene-1-carboxylic Acid (14a): Compound 14b was dissolved in a
mixture of THF/MeOH (83:17, 66 mL), and a solution of KOH
(603 mg, 10.7 mmol) in water (11 mL) was added. The mixture was
stirred at r.t. for 6 h, subsequently acidified with 1 M HCl until pH ≈
1, and extracted with EtOAc (4 × 100 mL). The combined organic
layers were dried with MgSO4 and concentrated by means of rotary
evaporation. The crude product was purified by column chromatog-
raphy (pentane/EtOAc/AcOH, gradient 90:9:1, 80:19:1 and 70:29:1)
to give 14a (978 mg, 2.30 mmol, 64 % yield) as an off-white crystal-
line solid. Mp 109–117 °C, 1H-NMR (400 MHz, CDCl3) δ = 7.68–7.58
(m, 4H), 7.84–733 (m, 6H), 4.44 (tt, J = 5.6, 4.0 Hz, 1H), 3.89 (s, 3H),
3.09–2.98 (m, 2H), 2.89–2.88 (m, 2H), 1.04 (s, 9H) ppm. 13C-NMR
(101 MHz, CDCl3) δ = 168.4, 163.1, 146.5, 135.63, 135.62, 135.55,
133.7, 133.4, 129.9, 129.8, 127.8, 127.7, 69.0, 53.7, 46.6, 45.3, 26.8,




Method 1, direct conversion of diester 14b. According to a modified
procedure,[14] ammonium chloride (331 mg, 6.19 mmol) was sus-
pended in toluene (10 mL). While cooling the suspension in an ice
bath, 2 M trimethylaluminium (solution in hexanes, 3.1 mL,
6.19 mmol) was added dropwise, after which evolution of methane
was observed. The ice bath was removed and the reaction mixture
was stirred at r.t. for 3 h. A solution of 14b (905 mg, 2.06 mmol)
in toluene (10 mL) was added dropwise to the reaction mixture,
subsequently the mixture was heated to 50 °C and stirred for 18 h.
The reaction mixture was cooled in an ice bath and quenched with
1 M HClaq (15 mL) and stirred for 15 min. The resulting clear biphasic
mixture was extracted with EtOAc (5 × 15 mL), the combined or-
ganic layers were dried with MgSO4 and concentrated in vacuo. The
crude product was purified by column chromatography, (pentane/
EtOAc, 60:40) affording 18 (467 mg, 1.10 mmol, 53 % yield) as a
pale brown crystalline solid.
Method 2, from acid-ester 14a. Following a modified literature proce-
dure,[11] to a solution of 14a (785 mg, 1.85 mmol) in CH2Cl2 (7.4 mL)
were added Et3N (1.0 mL, 748 mg, 7.40 mmol) and DMF (0.1 mL).
The mixture was cooled in an ice bath, and thionyl chloride (0.5 mL,
885 mg, 7.45 mmol) was added dropwise, followed by stirring for
15 min. The reaction mixture was added dropwise to an ice-cold
solution of concentrated 14 M NH4OHaq (100 mL) under vigorous
stirring, and the resulting turbid mixture was extracted with EtOAc
(3 × 50 mL), the combined organic layers were washed with brine
(50 mL), dried with MgSO4 and concentrated in vacuo. Purification
by column chromatography (pentane/EtOAc, 60:40) afforded 18
(420 mg, 0.99 mmol, 54 % yield) as a pale brown crystalline solid.
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7.59 (m, 4H), 7.51–7.30 (m, 6H), 5.91 (bs, 1H), 4.43 (pent., J = 5.1 Hz,
1H), 3.77 (s, 3H), 3.03–2.93 (m, 2H), 2.93–2.82 (m, 2H), 1.05 (s, 9H)
ppm. 13C-NMR (101 MHz, CDCl3) δ = 166.4, 165.7, 145.9, 135.65,
135.64, 134.0, 133.7, 132.2, 129.8, 129.7, 127.72, 127.67, 69.4, 52.4,
46.4, 45.6, 26.8, 19.1 ppm. HRMS calcd. for C24H29NO4Si [M + H]+:
424.1939, found 424.1920.
5-[(tert-Butyldiphenylsilyl)oxy]-5,6-dihydrocyclopenta[c]pyrr-
ole-1,3(2H,4H)-dione (19): A round bottomed flask was equipped
with a stir bar and NaH 60 % suspension in mineral oil (55 mg,
1.65 mmol) which was rinsed with pentane three times. A solution
of 18* (467 mg, 0.551 mmol) in THF (5.5 mL) was added dropwise
via syringe, while cooling the reaction mixture on ice. After 15 min,
when H2 evolution had ceased, the reaction mixture was quenched
by adding acetic acid (0.1 mL). The mixture was diluted with water
and extracted with EtOAc (4 × 15 mL), the combined organic layers
were dried with MgSO4 and concentrated in vacuo. Purification by
means of column chromatography (pentane/ether, 80:20) gave 19
(141 mg, 0.348 mmol, 65 % yield) as a colourless amorphous glass.
1H-NMR (400 MHz, CDCl3) δ = 7.67–7.62 (m, 4H), 7.51–7.36 (m, 6H),
7.02 (br s, 1H, NH), 4.93 (tt, J = 6.8, 3.9 Hz, 1H), 2.83–2.72 (m, 2H),
2.71–2.62 (m, 2H), 1.07 (s, 9H) ppm. 13C-NMR (101 MHz, MeOD) δ =
166.7, 151.2, 135.6, 133.2, 130.0, 127.9, 77.2, 37.1, 26.8, 19.0 ppm.
HRMS (negative mode) calcd. for C23H25NO3Si [M – H]–: 390.1531,
found 390.1530. *With this substrate it was occasionally observed
that the reaction did not initiate spontaneously. The addition of
1.3 equiv. of 15-crown-5 to the solution of the substrate prior before
adding it to the sodium hydride solved this problem, without affect-
ing the yield. Addition of 15-crown-5 potentially also prevents runa-
way reactions when the procedure is performed at larger scales.
5-Hydroxy-5,6-dihydrocyclopenta[c]pyrrole-1,3(2H,4H)-dione
(5): Compound 19 (140 mg, 0.385 mmol) was dissolved in THF, and
Bu4NF solution in THF (1 M, 0.72 mL, 0.72 mmol) was added drop-
wise. The solution was stirred for one hour at r.t. Then it was
quenched by adding saturated NH4Claq (10 mL) and the mixture
was extracted with EtOAc (6 × 20 mL). The combined organic layers
were dried with MgSO4 and concentrated in vacuo. The crude was
dry-loaded onto silica and placed on a short silica plug, which was
eluted with solvent (pentane/ether, 80:20, 250 mL), this fraction was
discarded. Then the plug was subsequently flushed with a second
portion of solvent (pentane/EtOAc, 50:50, 400 mL), concentration of
this fraction afforded the iso-maleimycin 5 (41.5 mg, 0.721 mmol,
76 % yield) as a white crystalline solid. Mp 94–101 °C, 1H-NMR
(400 MHz, MeOD) δ = 4.90 (tt, J = 6.4, 2.6 Hz, 1H), 2.99–2.88 (m*,
2H), 2.54–2.43 (m*, 2H) ppm. 13C-NMR (101 MHz, MeOD) δ = 168.4,
1531.3, 75.2, 35.9 ppm. HRMS (negative mode) calcd. for C7H7NO3
[M – H]–: 152.0353, found 152.0355. *These signals appear to form
a pair of distorted double doublets. However, due to long range
couplings, the true multiplicity cannot be determined.
Identification of Iso-maleimycin from S sp. QL37
Preparation of the Isolate: Streptomyces sp. QL37 was cultivated
on minimal media agar plates with 1 % glycerol and 0.5 % mannitol
(w/v) as the carbon sources. After seven days of growth at 30 °C,
the plates were cut into small blocks and the resultant agar pieces
were extracted with EtOAc (25 mL) by soaking overnight at room
temperature, the supernatant was removed and the extraction pro-
cedure was repeated two more times. The combined organic layers
were evaporated at room temperature. Subsequently the dried ex-
tract was re-dissolved in ethyl acetate and transferred to a new pre-
weighed vial. The extract was evaporated under reduced pressure
at 30 °C to determine the amount of extracted compounds.
GC-MS Analysis: For analysis and identification, synthetic samples
of maleimycin and iso-maleimycin (0.23 mg/mL), along with a sam-
Eur. J. Org. Chem. 2020, 5145–5152 www.eurjoc.org © 2020 The Authors published by Wiley-VCH GmbH5151
ple of the extract (1 mg/mL) were injected on a Shimadzu GC-2010
gas chromatograph coupled to a Shimadzu GC-MS-QP2010 gas
chromatograph mass spectrometer. For the synthetic samples, split
ratio 20.0, for the extract, split ratio 10.0. The injection temperature
was 200 °C, detector temperature 250 °C. Separation was carried
out on an HP-1 column, 100 % dimethylsiloxane, (30 m L × 0.25 mm
Ø × 0.25 μm thickness). The temperature program was set as fol-
lows: 150 °C hold for 5 min, then increase 150 °C to 200 °C with
20 °C/min, finally 3 minutes hold at 200 °C. The carrier gas was He,
with a column flow of 0.9 mL/min, pressure 82.7 kPa. Ionization by
means of EI, ionization energy 70 eV, mass range from m/z 50–225.
The identification was done by comparing retention times and mass
fragmentation patterns of the synthetic standards with those ob-
tained from the extracts.
Biological Assays
Disc Diffusion Assay with Soft Agar Overlay: The antimicrobial
properties of iso-maleimycin were determined by disc diffusion as-
say. Briefly, three colonies of the indicator strains, Bacillus subtilis
and Escherichia coli ASD19, were picked from an agar plate for the
inoculation of an overnight culture. Afterwards, 300 μL of the over-
night culture were added in 10 mL of fresh LB broth and incubated
at 37 °C until a OD600 of 0.3. Then, a LB plate was overlaid with LB
soft agar (0.75 % w/v agar) containing 1.5 mL from one of the indi-
cator strains pre-grown in liquid LB to OD600 of 0.3. When solidified,
antibiogram discs loaded with 10 μL of 1 mg/mL of iso-maleimycin
were applied on it and incubated overnight at 37 °C. Ampicillin
1 μg/mL was used as a control.
MIC Tests: The minimum inhibitory concentration (MIC) test was
determined by the broth microdilution method using the British
Standard BS EN ISO 20776–1:2006.[17,18] A stock solution of iso-
maleimycin 5 was made by dissolving it in Mueller-Hinton (MH)
broth to a concentration of 4 mg/mL. The bacterial indicator strains
(Escherichia coli ASD 19 and Bacillus subtilis) were grown for approxi-
mately two hours from an overnight culture until an OD600 of 0.3
in MH broth and diluted until a concentration of bacteria of 1 × 106
CFU mL–1 in fresh broth. 50 μL of MH broth were added to all the
wells of the 96-well polypropylene microtiter plates. Then, 50 μL of
the sample stock was added to the first row to the concentration
of 2000 μg/mL, which was serially twofold diluted. Subsequently,
50 μL of the indicator strains were added to the wells resulting in
a range of antibiotic concentration from 1000 μ/mL to 7 μg/mL.
Three replicates were performed for each indicator bacterial strain.
Growth control wells containing 100 μL of 5 × 105 CFU mL–1 were
included without test compounds. After overnight incubation at
37 °C, inhibition was defined as no visible growth compared to the
growth observed in the control wells. For iso-maleimycin results
were determined as 250 μg/mL for E. coli ASD19 and 250 μg/mL
for B. subtilis. As comparison, for maleimycin the results were deter-
mined as 31 μg/mL for E. Coli ASD19 and 125 μg/mL for B. Subtilis.
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